Kodiak Sciences Inc. (KOD)
Market Closed
11 Aug, 20:00
$
42. 11
-1.29
-2.9724%
$
2.84B Market Cap
- P/E Ratio
- Div Yield
507,980 Volume
-4.64 Eps
$ 43.4
Previous Close 
Want to track KOD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.
Zacks | 1 year ago
All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy
Kodiak Sciences (KOD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks | 2 years ago
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Zacks | 2 years ago
Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Zacks | 2 years ago
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
Zacks | 2 years ago
